Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.

Saved in:
Bibliographic Details
Title: Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Authors: Ittershagen S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. stacie.ittershagen@novartis.com., Ericson S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Eldjerou L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Shojaee A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Bleickardt E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Patel M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Taran T; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Anak O; Novartis Pharma AG, Basel, Switzerland., Hall C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Leung M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Roccoberton D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Salmon F; Novartis Pharma AG, Basel, Switzerland., Fuchs M; Novartis Pharma AG, Basel, Switzerland., Romanov V; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Lebwohl D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Source: Current hematologic malignancy reports [Curr Hematol Malig Rep] 2019 Feb; Vol. 14 (1), pp. 47-55.
Publication Type: Journal Article; Review
Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 101262565 Publication Model: Print Cited Medium: Internet ISSN: 1558-822X (Electronic) Linking ISSN: 15588211 NLM ISO Abbreviation: Curr Hematol Malig Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1558-822X
DOI:10.1007/s11899-019-0498-6